MMSI Medical Devices · Medtech · Mid cap · M&A · Thesis updated August 11, 2026

Margins expand and OEM sales recover to support the plan

Merit sells proprietary medical devices used in cardiology, radiology, oncology, critical care, endoscopy, and related procedures.
The bull case is gaining ground with record Q2 2026 non-GAAP operating margins of 22.6% and a successful OEM recovery.
The combination of the late May SCOUT MD launch and View Point Medical effectively triples the addressable breast biopsy market to 1.3 million procedures.
The bear case focuses on a volatile tariff environment, with the company raising its expected full-year 2026 tariff impact to roughly $16 million.
Finn's middle-of-the-road score reflects a solid execution story balanced against valuation questions and supply chain noise.

01 Running thesis

Margins rise while oncology expands

Merit is executing well on its Continued Growth Initiatives program. Full-year 2025 sales were $1.516 billion, and the momentum carried into 2026. In Q2 2026, non-GAAP operating margin reached an impressive 22.6%. The company is clearly finding ways to run more profitably under current leadership.

Growth is also getting a structural lift. Merit has bought useful assets, including View Point Medical in oncology and Biolife assets in cardiac therapies. The Biolife integration is outperforming, with annualized revenue expectations raised to $23 million. The View Point deal, combined with the May 2026 launch of SCOUT MD, expands the addressable breast biopsy market from roughly 400,000 procedures to 1.3 million procedures.

The bear case rests on headwinds that refuse to fade completely. OEM sales jumped 15% year over year in Q2, shaking off a steep drop in Q1, but investors still want to see that business maintain a steady mid-to-high single-digit growth rate. Tariffs also remain a headache. The company actually recognized a refund benefit in Q2 but still raised its projected 2026 tariff hit to roughly $16 million due to policy volatility.

The stock deserves credit for margin progress and a cleaner product lineup, especially after fixing the Renal supply chain issue. The proof points are appearing, but the $16 million tariff bill and potential hospital pricing pressure keep the story grounded.

Jul 2026▲Q2 2026 results showed non-GAAP operating margin reaching 22.6% and a 15% recovery in OEM sales. The SCOUT MD launch also tripled the addressable breast biopsy market.

Apr 2026▲Q1 2026 strengthened the margin story, with operating margin reaching a record 19.7%. The View Point Medical acquisition gave oncology a clearer growth path.

Apr 2026▼OEM sales fell 14% year over year in Q1 because of inventory destocking tied to product transfers. A Class I recall in the Renal segment was also disclosed.

Feb 2026▲FY2025 results supported the operating plan, with revenue of $1.516 billion, up 11.8%, and gross margin of 48.7%. Endoscopy grew 33.0% for the year.

Feb 2026→Merit sold the DualCap product line for $28 million. The move made the portfolio cleaner, but it did not change the central thesis by itself.

Oct 2025▲The CEO transition to Martha G. Aronson was completed. Q3 results also showed strong gross margins and added C2 CryoBalloon to the endoscopy portfolio.

02 Business model

Many small tools for serious procedures

Merit makes and sells medical devices used by doctors during interventional, diagnostic, and therapeutic procedures. These are not consumer products. They are tools used in hospitals, clinics, and procedure rooms, often in areas like cardiology, radiology, oncology, critical care, and endoscopy.

The business has two broad revenue buckets. Foundational products are access and enabling tools, and they represented about two-thirds of revenue entering 2026. Therapeutic products treat disease more directly, and they represent the other third. Therapeutic products are where Merit is trying to add more growth through oncology, endoscopy, renal, and cardiac therapies.

This model works well when Merit sells proprietary devices, improves factories, and folds acquired products into its sales force. It can stumble when hospital demand slows, OEM customers reduce inventory, shipping is delayed, tariffs lift costs, or recalls create operational noise.

03 Product portfolio

Where the growth can come from

Cash cow

Foundational access and enabling products

These products help doctors get into the body and perform procedures safely. They make up roughly two-thirds of revenue, funding much of the company.

Growth engine

Oncology and SCOUT MD

The May 2026 launch of SCOUT MD, paired with the OneMark system, expands the addressable breast biopsy market to roughly 1.3 million procedures.

Growth engine

Endoscopy

Endoscopy sales grew 33.0% in 2025. The newer C2 CryoBalloon technology and the Resilience TTS Esophageal Stent add more products for digestive disease care.

Option

WRAPSODY

WRAPSODY is a commercial growth target for 2026, with management aiming for $7 million of revenue as the launch tracks forward.

Steady

Cardiac therapies and Biolife

Merit added Cook Medical's lead management portfolio and Biolife assets. The Biolife integration is outperforming, with 2026 annualized revenue expectations raised to $23 million.

Steady

OEM products

Merit sells to other medical device companies. After a sharp drop in Q1 2026, this segment recovered with 15% growth in Q2.

04 Business segments

Two buckets now matter

Foundational67%modest

Therapeutic33%growing fast

Merit reports revenue as Foundational and Therapeutic. The mix below uses management's baseline disclosure entering 2026.

05 Risk factors

What could trip the plan

Tariff refund risk and rising costs

Medium impact · High odds

Merit raised its expected 2026 tariff headwind to roughly $16 million in Q2, despite securing a partial refund earlier. The policy environment is highly volatile, and if future refunds are denied, margin gains will be harder to protect.

We watchUpdates on tariff refund filings and any further changes to 2026 cost guidance.

OEM recovery stalls

Medium impact · Medium odds

OEM sales fell 14% in Q1 2026 due to destocking but rebounded with a 15% gain in Q2. Management expects sustainable mid-to-high single-digit growth annually, but more inventory noise could hurt revenue visibility.

We watchQuarterly OEM growth versus management's single-digit target.

View Point and SCOUT MD integration

Medium impact · Medium odds

The View Point Medical deal and SCOUT MD launch triple the addressable oncology market. That upside depends on Merit successfully integrating the products, training sales teams, and winning customers. A slow start would reduce the value of the deals.

We watchOncology revenue growth and commentary on SCOUT MD and OneMark adoption.

APAC and shipping disruption

Low impact · Medium odds

Geopolitical instability in the Middle East has prompted strategic inventory builds and a shift to ocean freight. Merit deferred some revenue earlier in the year due to shipping logistics. This can slowly chip away at growth.

We watchFreight surcharges, ocean transit times, and any repeated revenue deferrals tied to shipping.

06 Quick answers

In one breath

What does Merit Medical Systems do?

Merit makes medical devices used in interventional procedures, diagnostics, therapy, cancer care, critical care, and endoscopy. Its products are sold mainly to hospitals, doctors, and other medical device companies.

Why is the SCOUT MD launch important for Merit?

Combined with the View Point Medical acquisition, the SCOUT MD launch triples the addressable breast biopsy market from roughly 400,000 procedures to 1.3 million procedures.

What is the main risk for MMSI stock right now?

The biggest near-term checks are OEM consistency and tariffs. The company faces a roughly $16 million tariff headwind in 2026 due to a volatile policy environment.